Amyris partners with clean beauty platform SuperOrdinary to market Biossance skin care in China

06 Jan 2021 --- Synthetic biotechnology company Amyris is launching its Biossance Clean Beauty skincare brand into the Greater China market via a partnership with SuperOrdinary Group.

Amyris is active in the clean health and beauty markets through its consumer brands and a supplier of sustainable and natural ingredients. Meanwhile, SuperOrdinary is the leading clean beauty marketing platform in China for some of the world’s fastest growing brands.

“China is one of the largest growth markets for Clean Beauty and skincare and the Biossance brand is well positioned to join the winning portfolio represented by SuperOrdinary,” comments John Melo, president and CEO of Amyris.

“Our consumer brands experienced an excellent fourth quarter with Biossance leading the way, and we expect our consumer business to close out the fourth quarter with as much sales revenue as it recorded for all of 2019. We are excited to take this momentum we have with Biossance to the Chinese market.”

On track with its expansion strategy, Amyris recently closed a US$50 million transaction with DSM Nutritional Products. Under the terms of the agreement, Amyris is licensing DSM rights to assume the supply of farnesene – a bio-based compound – to Givaudan for the production and sale of a single specialty ingredient.

Growing Chinese clean beauty market
China is one of the largest and fastest growing beauty markets globally, and Chinese consumers are demanding sustainable products with clean ingredients, Amyris states. 

Amyris is launching its Biossance Clean Beauty skincare brand into the Greater China market.Biossance’s clean beauty attributes align with SuperOrdinary’s goal to bring more beauty and wellness brands to the China market. 

“We work with global beauty and cosmetics brands to establish and scale their influence and sales channels in China,” says Julian Reis, founder and CEO of SuperOrdinary Group. 

“We are happy to partner with Amyris to bring its leading Biossance Clean Beauty brand to the Chinese consumer. We have a proven track record of working with high growth brands such as Biossance and are looking forward to delivering on Amyris’s vision for the Greater China market.”

On Amyris’ expansion politics
Amyris is a science and technology player in the research, development and production of sustainable ingredients for the clean health and beauty and flavors and fragrances markets. 

The company uses an array of exclusive technologies, including machine learning, robotics and artificial intelligence. Its ingredients are included in over 3,000 products from global brands, reaching more than 200 million consumers. 

Within its portfolio are Biossance, Pipette, a clean baby skincare, and Purecane, a zero-calorie sweetener naturally derived from sugarcane. 

In September, the company scaled up the commercial production of cannabigerol (CBG), a fermentation-based alternative to cannabidiol (CBD) after having scored US$300 million to develop a new cannabinoid in 2019. 

Earlier this year, Amyris entered into definitive securities purchase agreements in a US$112 million recapitalization anchored by Foris Ventures. In expansion moves toward the Chinese market, it signed an agreement with Xinfu of China for a long-term minimum annual share of an existing nutritional product royalty arrangement. 

By Kristiana Lalou